Prediction of postoperative recurrences by gene expression profiling in patients with primary resected lung cancer

我们分析了LCNEC的基因表达、基因突变和已知分子靶点的免疫组化表达，并将其与肺腺癌的表达进行了比较。我们分析了13例原发性LCNEC和14例腺癌（AC）患者。我们评估了c-KIT、人表皮生长因子受体2型（HER 2）和血管内皮生长因子（VEGF）的免疫组织化学（IHC）表达，EGFR、K-ras和c-kit的基因突变，以及EGFR的荧光原位杂交（FISH）基因表达。在LCNEC病例中，c-KIT、HER 2和VEGF的免疫组化表达分别为76.9%、30.8%和100%。LCNEC和AC中c-KIT和HER 2的IHC表达存在显著差异。2例LCNEC有HER 2过表达，AC组EGFR基因突变较多，LCNEC组仅发现1个EGFR突变（外显子18）。尽管LCNEC中c-KIT的表达率较高，但未发现c-kit基因突变，提示抗VEGF、抗c-KIT和抗HER 2靶向药物在LCNEC治疗中可能具有潜在作用。

We analyzed LCNEC gene expression, gene mutation and immunohistochemical expression of known molecular targets and compared expression to that of lung adenocarcinomas. We analyzed 13 patients with primary LCNEC and 14 patients with adenocarcinoma(AC). We evaluated immunohistochemical(IHC) expression for c-KIT, human epidermal growth factor receptor type 2(HER2), and vascular endothelial growth factor(VEGF), gene mutation for EGFR, K-ras and c-kit, and gene expression using fluorescence in situ hybridization(FISH) for EGFR. In cases with LCNEC, the IHC expression of c-KIT, HER2, and VEGF were 76.9%, 30.8%, and 100%, respectively. There was a significant difference in IHC expression in c-KIT and HER2 between LCNEC and AC. Two cases of LCNEC had overexpression of HER2, and EGFR gene mutation was greater in the AC group, with only a single EGFR mutation(exon 18) identified in the LCNEC group. Although LCNEC had a higher rate of expression of c-KIT by IHC, no c-kit gene mutations were found. These findings suggest a potential role for Anti-VEGF, Anti-c-KIT, and possibly Anti-HER2 targeted agents in the treatment of LCNEC.